Breaking News, Financial News

Financial Report: Hospira 4Q

Growth in the quarter was driven by an increase in Specialty Injectable Pharmaceuticals, with sales in the Americas up 27% to $439.2 million, in Europe, Middle East & Africa, sales were $76.7 million (+21%), and in the Asia Pacific region, sales were

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Hospira 4Q 4Q Revenues: $1.1 billion (+16%) 4Q Earnings: $97.0 million (-8%) FY Revenues: $3.9 billion (+7%) FY Earnings: $403.9 million (+26%) Comments: Growth in the quarter was driven by an increase in Specialty Injectable Pharmaceuticals, with sales in the Americas up 27% to $439.2 million, in Europe, Middle East & Africa, sales were $76.7 million (+21%), and in the Asia Pacific region, sales were $62.4 million (+25%). The company launched the generic chemotherapy agent ox...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters